Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Thromb Res. 2018 Apr;164 Suppl 1:S54-S61. doi: 10.1016/j.thromres.2018.01.017.
Malignant disease is characterized by a hemostatic imbalance, usually shifted towards a procoagulant direction, and a high incidence of thrombotic complications. The mechanisms of hemostasis that are critically involved in thrombosis are also implicated in tumor progression, angiogenesis, and metastatic spread. As there is a close relationship between cancer and the clotting system, circulating biomarkers of activation of various hemostasis compartments (i.e. coagulation, fibrinolysis, platelets, endothelium, and other blood cells) have been extensively studied to predict cancer outcomes along with predicting the thrombotic risk. In this review, we will summarize the results of published studies and will focus on ongoing research and future directions of clotting activation bioproducts as biomarkers of cancer disease and progression.
恶性疾病的特征是止血失衡，通常向促凝方向转变，并且血栓并发症的发生率很高。在血栓形成中起关键作用的止血机制也与肿瘤的进展、血管生成和转移扩散有关。由于癌症与凝血系统之间存在密切关系，因此已广泛研究了各种止血成分（即凝血、纤溶、血小板、内皮细胞和其他血细胞）的激活的循环生物标志物，以预测癌症的预后以及血栓形成的风险。在这篇综述中，我们将总结已发表研究的结果，并重点介绍正在进行的研究以及凝血激活生物标志物作为癌症疾病和进展的标志物的未来方向。
